It was a pleasure to meet with Prof. Tobias Welte (Medizinische Hochschule, Hannover, Germany), following his keynote presentation, to continue the discussion around COVID-19 management, current vaccine approaches and promising agents in clinical development.
1. What are the major obstacles to be overcome in the investigation of management and preventative strategies for COVID-19? (0:37)
2. In your opinion, what are the most promising agents in clinical development for COVID-19 treatment? (2:47)
3. What progress has been made in the development of monoclonal antibody therapies? (5:14)
4. Could you give us a brief overview of the status of the major vaccine trials worldwide? (6:18)
5. What have we learned in terms of improving the efficiency of vaccine studies? (9:23)
Speaker disclosure: Tobias Welte has received research grants from the DFG, BMBF, EU, and WHO. He has also received lecture fees from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Berlin Chemie GSK, Infectopharm, MSD, Novartis, Pfizer, Roche and acted as an advisory board member for AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Gilead, GSK, Janssens, Novartis, Pfizer and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In COVID-19
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Dr Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing […]
Ivan Gentile, ERS 2020 – Outcome Prediction in COVID-19 Patients
Following the ERS International Congress, we were delighted to catch up with Prof. Ivan Gentile to further discuss the topic of his presentation entitled ‘Severity Assessment and Outcome Prediction in COVID-19 Patients‘. Questions 1. Why do levels of C-reactive protein (CRP) increase during COVID-19? (0:20) 2. How can CRP testing inform severity assessment and outcome […]
Sara De Matteis, ERS 2020 – Air Pollution and COVID-19 Mortality
We discuss with Prof. Sara De Matteis (University of Cagliari, Cagliari, Italy) what we know so far about the potential association between air pollution exposure and SARS-CoV-2 infection. Questions 1. Could you give us a brief overview of the potential association between air pollution exposure and SARS-CoV-2 infection? (0:34) 2. What is the biological plausibility […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!